Intra-Cellular Ther (ITCI) 22.71 $ITCI Intra-Cellular

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Intra-Cellular Ther (ITCI) 22.71 $ITCI

Intra-Cellular Therapies to Host First Quarter 2015 Financial Results Conference Call and Webcast
GlobeNewswire - Fri Apr 24, 7:00AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:00 a.m. Eastern Time on Thursday, April 30, 2015, to discuss financial results for the first quarter ended March 31, 2015, and provide a business update.
ITCI: 22.71 (-1.26)

Is Intra-Cellular Therapies (ITCI) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 7:53AM CDT
Intra-Cellular Therapies is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
ITCI: 22.71 (-1.26)

Intra-Cellular Therapies Presents the ITI-007 Clinical Development Program at the 15th International Congress on Schizophrenia Research
GlobeNewswire - Tue Mar 31, 7:00AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, presented data regarding the ITI-007 development program and described the rationale supporting the strategy for the advancement of ITI-007 in multiple clinical indications at the 15th International Congress on Schizophrenia Research (ICOSR) in Colorado Springs.
ITCI: 22.71 (-1.26)

Intra-Cellular Therapies to Present at the 15th International Congress on Schizophrenia Research
GlobeNewswire - Wed Mar 25, 7:00AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it is scheduled to make presentations regarding its ITI-007 schizophrenia program at the 15th International Congress on Schizophrenia Research (ICOSR) in Colorado Springs, March 28th - April 1st 2015.
ITCI: 22.71 (-1.26)

Intra-Cellular Therapies concludes USD130m in public offering
M2 - Thu Mar 12, 6:52AM CDT
Biopharmaceutical company
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innventure Faces Major Lawsuit Over Misleading Investors

Updated Category News Views 2

Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...

Continue Reading
Voter Events by Valley Community Healthcare Aim to Empower

Updated Category News Views 1

Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....

Continue Reading
AEVEX Facing Class Action Deadline Amid Stock Turmoil

Updated Category News Views 3

Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...

Continue Reading
LG OLED evo W6: UAE Roadshow Starts with a Bang

Updated Category News Views 2

They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...

Continue Reading
Hyliion Class Action Deadline Nears for Investors

Updated Category News Views 1

Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...

Continue Reading
Masimo's smartSET™ Revolutionizes Patient Monitoring

Updated Category News Views 2

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Continue Reading
Weifang's Cultural Resurgence: A Global Epigraphy Fest

Updated Category News Views 3

A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming $100 Into Significant Wealth with MANH Stock

Updated Category News Views 175

Unlocking Wealth: The Manhattan Associates Investment Narrative Let’s dive into a real financial gem that’s often overshadowed by bigger names—Manhattan Associates (NASDAQ: MANH). This company isn’t just another name in the tech universe; it’s been killing it in the stock market arena with an annualized growth rate that clocks in at 18.87%. If you crunch those...

Continue Reading
Investors Alert: Class Action Opportunities with Law Offices

Updated Category News Views 176

Class Action Lawsuits Overview Investors are being reminded about important class action lawsuits related to several publicly-traded companies. These class actions provide shareholders an opportunity to seek justice for alleged securities fraud. The Law Offices of Howard G. Smith has initiated these lawsuits, urging affected investors to explore their legal options....

Continue Reading
Brink's Announces Earnings Call for Upcoming Financial Results

Updated Category News Views 136

Brink's Company Earnings Call Announcement RICHMOND, Va. — The Brink’s Company (NYSE: BCO), a premier global provider specializing in cash and valuables management, digital retail solutions, and ATM managed services, has announced that it will conduct a conference call to discuss the financial results from the second-quarter of the year. This event is slated for...

Continue Reading
Significant New Share Offering by DSV A/S Bolsters Financial Growth

Updated Category News Views 203

DSV A/S finalized a hefty equity offering that raised DKK 37.3 billion—about EUR 5 billion—in early 2024. They dropped a massive 26,444,523 new shares on the market to shore up their finances for the acquisition of Schenker AG from Deutsche Bahn. Traders were quick to gauge what this meant: a serious boost in their logistics game. Equity Offering Details: What's...

Continue Reading
AmacaThera Partners with Pacira BioSciences in Major Deal

Updated Category News Views 130

AmacaThera Develops Game-Changing Partnership with Pacira BioSciences AmacaThera has recently entered into a significant exclusive global licensing agreement with Pacira BioSciences, marking a pivotal moment for the innovative drug delivery company. This partnership is centered around AMT-143, AmacaThera's advanced long-acting non-opioid anesthetic designed for...

Continue Reading